+1 (310) 820-8100
info@biosigtech.com

LETTER TO SHAREHOLDERS

Los Angeles, June 14, 2019

Dear Shareholder,

I wanted to take the opportunity to provide a detailed mid-year update on your Company's progress and outlook for the balance of 2019. BioSig continues to deliver on the milestones it has set forth to the market and its shareholders, and so much has already been achieved in the first five months of 2019.

I would like to start with a paragraph taken from our Annual Shareholder Letter from February 2019:

"We envisage bringing our technology into at least three more leading centers following the initial First in Human ("FIH") experience in the first half of 2019 and then expanding the base of users to include many other centers that are known as the early adopters of new technology. They will be evaluating the features and benefits of our technology, giving us important insight into the first leg of commercialization. Should that process produce expected results, we intend to expand our commercial efforts in the second half of 2019 and prepare for a steeper curve in 2020".

Keeping our promises

We have been very fortunate with our first clinical cases, which were performed at Texas Cardiac Arrhythmia Institute, Greenville Memorial Hospital and Indiana University. The PURE EP™ System was utilized on 22 patients with various forms of arrhythmia, from atrial fibrillation to atypical flutter to ventricular tachycardias and a rare case of dual septal pathway, and the system performed above our expectations. Each case provided physicians and our clinical team with an indispensable learning experience about the role certain heart signals play in understanding arrhythmias.

First presentations at the 40th Heart Rhythm Society Scientific Sessions

Our management, Board of Directors and key advisors were on hand for our very first public presentation at the 40th Heart Rhythm Society Scientific Sessions in San Francisco in May 2019. Physicians and administrators from over 60 hospitals, many of whom are considered the most renowned key opinion leaders in the industry, came over to our booth to learn more about our first clinical experience and receive a demo of PURE EP™ System.

We were also grateful to see some of our shareholders, who travelled to San Francisco from all over the world to share this special day with us.

+1 (310) 820-8100
info@biosigtech.com

First success achieved: what's next?

We have been studying successes and failures of the medtech industry from the very beginning of BioSig. What has become clear to management over the years is that the most successful medical device companies generally follow a similar path to market: the so-called ***"crawl, walk, run"***: **'crawl'** with a small, highly targeted number of early technology adopters to identify the most vital elements of value proposition; proceed to **'walk'** by gradually increasing the number of centers and introduction of more enhanced technology features and, finally, **'run'** with a strong market positioning and a nationwide base of customers.

The '**crawl**' phase typically consists of two segments: (a) first clinical cases and (b) external evaluation. With the first phase successfully completed, we are working on bringing our PURE EP™ System to five more leading hospitals over coming months and install our technology, under contract, for a period of up to 90 days. At the end of the 90-day period, we intend to engage the hospitals to purchase our system and software.

During this time, physicians and lab staff will use our system on a wide range of arrhythmia cases with the Company's support on installation, training, operation of the technology, and case support. In exchange, we expect to receive valuable human clinical data, which should serve as a foundation for future evidence-based clinical trials and broader publication strategy (see below for more information).

We are receiving 15 new units of PURE EP™ System from our manufacturing partner Minnetronix, which will be used in the external evaluation process described above – we intend to name the centers to receive our technology shortly via official public announcements. We expect this process to go through Q3 and Q4 2019. During this time, we continue to grow our team on the clinical, sales, marketing, and technical side so we can support the planned customer expansion at more hospitals around the U.S. and expected growth in 2020.

The first five centers are expected to also serve as training sites to assist new centers in learning and training on our technology.

To summarize, the Company's strategy for the balance of the year is consistent with the guidance we provided our shareholders in February this year.

We expect 2020 to be a strong year of growth and expansion for BioSig and PURE EP™ System.

Growing our publication strategy

All data collected from our first clinical sites will be analyzed, published in and presented to leading medical journals and conferences. This can be a lengthy process, but one that should strengthen the value proposition of our technology and help our sales and marketing teams drive systems sales.

+1 (310) 820-8100
info@biosigtech.com

We have identified a number of high-profile industry events both in the U.S. and Europe that we plan to present our data to. We recently announced that our team will be presenting our latest publication entitled *"Evaluation of Real Time Catheter Tissue Contact using Unipolar Intracardiac Signal Morphology"* at the 41st International Engineering in Medicine and Biology Conference (EMBC) coming up in Berlin, Germany in late July. This manuscript was prepared based on the strong data collected during pre-clinical studies at Mayo Clinic in Rochester, Minnesota, and we expect it to be well received.

Adding more human talent

BioSig has been very successful in attracting quality talent to fill leadership roles in the Company. John Kowalski, our Vice President of Sales, left a 24-year long career at Johnson & Johnson's Biosense Webster, the leading player in our space, in a top sales leadership role to join our Company early February. John has been an excellent addition to our team.

Shortly afterwards, we appointed Dr. Barry Keenan, Ph.D, MBA, PMP as Vice President of Engineering. Dr. Keenan came from the Alfred Mann Foundation for Scientific Research, where he drove development of innovative medical devices, including implanted neuromodulation and sensing systems. Prior to that, Dr. Keenan enjoyed a successful engineering career at Medtronic, having brought the world's first artificial pancreas project from inception to highly successful commercialization. Dr. Keenan won global recognition for this achievement, as his invention was featured in Time magazine's 25 Best Inventions of 2013 and 2016 and named as one of the Best Medical Technologies of 2016.

We also strengthened our already solid Board of Directors. Dr. Jerome B. Zeldis, M.D., Ph.D, former Chief Medical Officer of Celgene, joined our Board in May 2019, and we have been interviewing a number of leading candidates for further expansion of our Board.

Bolstering IP for long-term commercial success

In 2017, we partnered with Silicon Valley-based Sherpa Technology Group, a leading IP strategy firm, and Sterne Kessler, a leading patent law firm, to build a robust IP strategy around our core competency in signal processing.

We were allowed 33 patent claims covering PURE EP™ System in Q2 2019. We expect to have a portfolio of up to 100 patents protecting our PURE EP™ System and the PURE EP™ Simulator as a result of these claims. We filed a number of applications with Mayo Foundation for Medical Education and Research as a co-assignee alongside BioSig.

We plan to continue to grow the value of our Company by bolstering our IP portfolio by capturing critical future inventions, design and software modules to ensure solid positioning in the EP signal processing IP space.

+1 (310) 820-8100
info@biosigtech.com

Solidifying our balance sheet to support growing operations

We are pleased with the capital appreciation of our share price this year of 59% year-to-date as of the writing of this letter. This is approximately 3x the rise in the S&P 500 or Russell 2000 for the same period.

In February 2019, the Company raised approximately $8.6 million of new monies, coming mostly from existing shareholders. We also received almost $4.6 million of cash in warrant and options exercises, bringing the total capital raised to over $13 million. This capital, plus what the Company had on hand, should allow us to continue our growth for at least a year without having to raise additional funds.

Ongoing insider buying also continues to demonstrate our interest and commitment to our Company.

On Friday June 7, FTSE Russell added BSGM to the Russell 3000® index, effective after the U.S. market opens on July 1, 2019. Being added to this broad-market, well-traded index is both a reflection of our growth and recognition of our progress. By inclusion in the Russell 3000®, we will also be enrolled in the Russell 2000® Small Cap index as well.

The Company now has over 4,000 beneficial shareholders in over 25 countries. Leading by fundamentals, we have never been stronger as a Company and never been more committed to our mission. We thank all our loyal shareholders for their continued support.

It is an honor to serve on your behalf.

With best wishes,

Ken Londoner
Founder, Chairman and CEO